Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Decreased by LSV Asset Management

LSV Asset Management decreased its stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 42.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,300 shares of the company’s stock after selling 12,600 shares during the period. LSV Asset Management’s holdings in Pacira BioSciences were worth $326,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of PCRX. PNC Financial Services Group Inc. lifted its holdings in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after buying an additional 513 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after acquiring an additional 918 shares in the last quarter. Caitlin John LLC lifted its stake in Pacira BioSciences by 1,850.0% during the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock worth $35,000 after purchasing an additional 1,776 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in Pacira BioSciences by 17.4% in the fourth quarter. Teacher Retirement System of Texas now owns 13,708 shares of the company’s stock worth $258,000 after purchasing an additional 2,034 shares during the period. Finally, Global Alpha Capital Management Ltd. increased its stake in Pacira BioSciences by 5.7% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 39,900 shares of the company’s stock valued at $752,000 after purchasing an additional 2,160 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on PCRX. Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and lifted their target price for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Pacira BioSciences in a research report on Tuesday, April 8th. HC Wainwright raised their price target on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a report on Tuesday, April 8th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $26.67.

Pacira BioSciences Stock Down 0.4 %

Shares of Pacira BioSciences stock opened at $24.88 on Wednesday. Pacira BioSciences, Inc. has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a market capitalization of $1.15 billion, a P/E ratio of -12.26 and a beta of 0.71. The business’s fifty day moving average price is $24.67 and its two-hundred day moving average price is $20.96. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.25 and a quick ratio of 1.89.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.